Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of S-892216 in Participants Infected With SARS-CoV-2 (COVID-19)
jRCT2031250144Phase 2Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing S-892216 with Placebo (2 arms). Primary endpoint: Change from baseline in SARS-CoV-2 viral RNA level by qRT-PCR on day 4. Started Jun 2025; status: active, not recruiting.
02
Drugs
S-892216
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031250144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250144.